-
EP2233486
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2233486
| EP2233486 - Azaindoles [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 14.10.2011 Database last updated on 20.05.2024 | Most recent event Tooltip | 14.10.2011 | Application deemed to be withdrawn | published on 16.11.2011 [2011/46] | Applicant(s) | For all designated states Aventis Pharma Limited Aventis House, 50 Kings Hill Avenue, Kings Hill West Malling Kent ME19 4AH / GB | [2010/39] | Inventor(s) | 01 /
Cox, Paul Joseph Aventis Pharma Limited Aventis House 50 Kings Hill West Malling, Kent ME19 4AH / GB | 02 /
Majid, Tahir Nadeem Aventis Pharma Limited Aventis House 50 Kings Hill West Malling, Kent ME19 4AH / GB | 03 /
Morley, Andrew David Aventis Pharma Limited Aventis House 50 Kings Hill West Malling, Kent ME19 4AH / GB | 04 /
Amendola, Shelley Aventis Pharma Limited Aventis House 50 Kings Hill West Malling, Kent ME19 4AH / GB | 05 /
Deprets, Stephanie Aventis Pharma Limited Aventis House 50 Kings Hill West Malling, Kent ME19 4AH / GB | 06 /
Edlin, Chris Aventis Pharma Limited Aventis House 50 Kings Hill West Malling, Kent ME19 4AH / GB | 07 /
Gardner, Charles J Aventis Pharma Limited Aventis House, 50 Kings Hil West Malling, Kent ME19 4AH / GB | 08 /
Kominos, Dorothea Aventis Pharma Limited Aventis House 50 Kings Hill West Malling, Kent ME19 4AH / GB | 09 /
Pedgrift, Brian Leslie Aventis Pharma Limited Aventis House 50 Kings Hill West Malling, Kent ME19 4AH / GB | 10 /
Halley, Frank Aventis Pharma Limited Aventis House 50 Kings Hill West Malling, Kent ME19 4AH / GB | 11 /
Lai, Justine Yeun Quai Aventis Pharma Limited Aventis House 50 Kings Hill West Malling, Kent ME19 4AH / GB | 12 /
Gillespy, Timothy Alan Aventis Pharma Limited Aventis House 50 Kings Hill West Malling, Kent ME19 4AH / GB | 13 /
Edwards, Michael Aventis Pharma Limited Aventis House 50 Kings Hill West Malling, Kent ME19 4AH / GB | 14 /
Clerc, Francois Frederic Aventis Pharma Limited Aventis House 50 Kings Hill West Malling, Kent ME19 4AH / GB | 15 /
Nemecek, Conception Aventis Pharma Limited Aventis House 50 Kings Hill West Malling, Kent ME19 4AH / GB | 16 /
Houille, Olivier Aventis Pharma Limited Aventis House 50 Kings Hill West Malling, Kent ME19 4AH / GB | 17 /
Damour, Dominique Aventis Pharma Limited Aventis House 50 Kings Hill West Malling, Kent ME19 4AH / GB | 18 /
Bouchard, Herve Aventis Pharma Limited Aventis House 50 Kings Hill West Malling, Kent ME19 4AH / GB | 19 /
Bezard, Daniel Aventis Pharma Limited Aventis House 50 Kings Hill West Malling, Kent ME19 4AH / GB | [2010/39] | Representative(s) | Pugh, Eilidh Ruth AdamsonJones BioCity Nottingham Pennyfoot Street Nottingham, Nottinghamshire NG1 1GF / GB | [N/P] |
| Former [2010/39] | Benest, Eilidh Ruth AdamsonJones BioCity Nottingham Pennyfoot Street Nottingham, Nottinghamshire NG1 1GF / GB | Application number, filing date | 09171579.7 | 20.06.2002 | [2010/39] | Priority number, date | GB20010015109 | 21.06.2001 Original published format: GB 0115109 | US20010300257 | 22.06.2001 Original published format: US 300257 | [2010/39] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP2233486 | Date: | 29.09.2010 | Language: | EN | [2010/39] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 25.08.2010 | Classification | IPC: | C07D471/04, C07D487/04, A61K31/437, A61K31/4985, A61P29/00, A61P11/00, A61P9/00, A61P35/00 | [2010/39] | CPC: |
C07D519/00 (EP,US);
C07D471/04 (EP,KR,US);
A61P11/00 (EP);
A61P11/02 (EP);
A61P11/06 (EP);
A61P13/08 (EP);
A61P17/00 (EP);
A61P17/02 (EP);
A61P17/06 (EP);
A61P19/02 (EP);
A61P27/14 (EP);
A61P29/00 (EP);
A61P35/00 (EP);
A61P37/08 (EP);
A61P43/00 (EP);
| Designated contracting states | AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR [2010/39] | Extension states | AL | Not yet paid | LT | Not yet paid | LV | Not yet paid | MK | Not yet paid | RO | Not yet paid | SI | Not yet paid | Title | German: | Azaindole | [2010/39] | English: | Azaindoles | [2010/39] | French: | Azaindoles | [2010/39] | Examination procedure | 30.03.2011 | Application deemed to be withdrawn, date of legal effect [2011/46] | 12.05.2011 | Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time [2011/46] | Parent application(s) Tooltip | EP02730531.7 / EP1397360 | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20020730531) is 28.07.2004 | Fees paid | Renewal fee | 29.09.2009 | Renewal fee patent year 03 | 29.09.2009 | Renewal fee patent year 04 | 29.09.2009 | Renewal fee patent year 05 | 29.09.2009 | Renewal fee patent year 06 | 29.09.2009 | Renewal fee patent year 07 | 29.09.2009 | Renewal fee patent year 08 | 11.06.2010 | Renewal fee patent year 09 | Penalty fee | Additional fee for renewal fee | 30.06.2011 | 10 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO9847899 (ORTHO MCNEIL CORP INC [US]) [A] 1-16 * abstract *; | [A]WO9920624 (HOFFMANN LA ROCHE [CH]) [A] 1-16 * example 17(2) * * examples 20-22; claims 1,18 *; | [A]WO0017202 (BASF AG [DE], et al) [A] 1-16 * claims 1,16,18,20 *; | [A]EP1086950 (CHUGAI PHARMACEUTICAL CO LTD [JP]) [A] 1-16 * examples 1(4), 3(3), 5(4), 6(3), 11(3) *; | [XP]WO0147922 (AVENTIS PHARMA LTD [GB], et al) [XP] 1-16 * whole document *; | [XP]WO0196336 (WARNER LAMBERT CO [US], et al) [XP] 1-16* page 10, lines 11-20, page 11, lines 21-30, claims 1,3,11,37,40-42 * | by applicant | US5750723 | - S.K.HANKS; T.HUNTER, FASEB. J., (1995), vol. 9, pages 576 - 596 | - A.C.NEWTON, J. BIOL. CHEM., (1995), vol. 270, pages 28495 - 28498 | - J.PINES, TRENDS INBIOCHEMICAL SCIENCES, (1995), vol. 18, pages 195 - 197 | - S.IWASHITA; M.KOBAYASHI, CELLULAR SIGNALLING, (1992), vol. 4, pages 123 - 132 | - C.CHAN, ANN. REV. IMMUNOL., (1994), vol. 12, pages 555 - 592 | - M.RETH, NATURE, (1989), vol. 338, pages 383 - 384 | - N.S.VAN OERS; A.WEISS, SEMINARS IN IMMUNOLOGY, (1995), vol. 7, pages 227 - 236 | - P.S.COSTELLO, ONCOGENE, (1996), vol. 13, pages 2595 - 2605 | - A.M.CHENG, NATURE, (1995), vol. 378, pages 303 - 306 | - D.H.CHU ET AL., IMMUNOLOGICAL REVIEWS, (1998), vol. 165, pages 167 - 180 | - S.YOUSEFI ET AL., J. EXP. MED., (1996), vol. 183, pages 1407 - 1414 | - M.ISHIAI ET AL., IMMUNITY, (1999), vol. 10, pages 117 - 125 | - L.R.HENDRICKS-TAYLOR ET AL., J.BIOL. CHEM, (1997), vol. 272, pages 1363 - 1367 | - M.FARIS ET AL., J.EXP. MED., (1994), vol. 179, pages 1923 - 1931 | - F.YANAGA ET AL., BIOCHEM. J., (1995), vol. 311, pages 471 - 478 | - SIEG ET AL., J. CELL SCIENCE, (1999), vol. 112, pages 2677 - 2691 | - RICHARDSON A.; PARSONS T., CELL, (1997), vol. 97, pages 221 - 231 | - XU ET AL., CELL GROWTH DIFFER., (1996), vol. 4, pages 413 - 418 | - JEKUNEN ET AL., CANCER TREATMENT REV., (1997), vol. 23, pages 263 - 286 | - EMBO J, (1998), vol. 17, pages 3052 - 3065 | - BASERGA R., "The IGF-I receptor in cancer research", EXP CELL RES., (1999), vol. 253, pages 1 - 6 | - BASERGA R., "The contradictions of the IGF1-Receptor", ONCOGENE, (2000), vol. 19, pages 5574 - 81 | - KHANDWALA HM. ET AL., "The effects ofIGFs on tumorigenesis and neoplastic growth", ENDOCRINE REVIEWS, (2000), vol. 21, pages 215 - 44 | - ADAMS TE ET AL., "Structure and function of the IGFIR", CMLS, (2000), vol. 57, pages 1050 - 93 | - LIPINSKI, ANNUAL REPORTS IN MEDICINAL CHEMISTRY, (1986), vol. 21, page 283 | - YUN; HWAHAK SEKYE, BIOISOSTERISM IN DRUG DESIGN, (1993), vol. 33, pages 576 - 579 | - ZHAO; HUAXUE TONGBAO, APPLICATION OF BIOISOSTERISM TO NEW DRUG DESIGN, (1995), pages 34 - 38 8 | - GRAHAM, "Bioisosteric Replacement And Development Of Lead Compounds In Drug Design", THEOCHEM, (1995), vol. 343, pages 105 - 109 | - F.J.LEINWEBER, DRUG METAB. RES., (1987), vol. 18, page 379 | - BUNDGAARD, J. MED. CHEM., (1989), vol. 32, pages 2503 - 2507 | - DAVIS ET AL., TETRAHEDRON, (1992), vol. 48, pages 939 - 952 | - CHANG; BAG, J.ORG.CHEM., (1995), vol. 21, pages 7030 - 7032 | - SAULNIER; GRIBBLE, J.ORG.CHEM., (1982), vol. 47, page 1982 | - W-W. SY, SYNTH.COMM., (1992), vol. 22, pages 3215 - 3219 | - YOSHIDA, J.HET.CHEM., (1995), vol. 32, page 701 | - CABELLA, TETRAHEDRON, (1995), vol. 51, no. 6, pages 18 - 17 | - TETRAHEDRON LETTERS, (1972), vol. 52, pages 5337 - 5340 | - SYNTHETIC COMMUNICATIONS, (1995), vol. 25, no. 6, pages 795 - 802 | - A. IPPOLITO ET AL., J. MED. CHEM., (1982), vol. 25, no. 10, pages 1258 - 61 | - D. HANDS ET AL., SYNTHESIS, (1996), pages 877 - 882 | - BENIGNI, J. D.; MINNIS, R.L., J. HETEROCYCL. CHEM., (1965), vol. 387, page 2 | - 1. A. BENAGES ET AL., J. ORG. CHEM., (1978), vol. 43, no. 22, pages 4273 - 6 | - A. PADWA ET AL., J. AM. CHEM. SOC., (1986), vol. 108, no. 21, pages 6739 - 46 | - A. R. KATRITZKY ET AL., HETEROCYCLES, (1997), vol. 44, pages 67 - 70 | - P.EASTWOOD, TETRAHEDRON LETTERS, (2000), vol. 41, pages 3705 - 3708 | - MARTINS ET AL., J. HETEROCYCL. CHEM., (1999), vol. 36, no. 1, pages 217 - 220 | - BENIGNI, J. D.; MINNIS, R. L., J. HETEROCYCL. CHEM., (1965), vol. 2, page 387 | - SINHABABU, A. K.; BORCHARDT, R. T., J. ORG. CHEM., (1983), vol. 48, page 3347 | - G.MATHIS ET AL., ANTICANCER RESEARCH, (1997), vol. 17, pages 3011 - 3014 | WO2000US15181 |